Condition
Neoantigen
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Unknown1
Terminated1
Recruiting1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06682117Not ApplicableRecruiting
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
NCT06499025Early Phase 1Enrolling By Invitation
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
NCT04923802Terminated
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)
NCT05498168Unknown
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
Showing all 4 trials